ARS Pharmaceuticals (SPRY) director receives 30,000 stock options at $10.54 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ARS Pharmaceuticals director Phillip M. Schneider received a grant of stock options as compensation. On June 24, 2026, he was awarded options covering 30,000 shares of common stock with an exercise price of $10.54 per share. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting and expire on June 23, 2036. After this grant, Schneider holds 30,000 stock options directly, and the transaction does not involve any open-market buying or selling of shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
SCHNEIDER PHILLIP M
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 30,000 options
Exercise price: $10.54 per share
Underlying shares: 30,000 shares
+3 more
6 metrics
Stock options granted
30,000 options
Grant to director on June 24, 2026
Exercise price
$10.54 per share
Strike price of stock option grant
Underlying shares
30,000 shares
Common stock underlying the options
Post-grant option holdings
30,000 options
Total derivative position following transaction
Vesting date
Earlier of June 24, 2027 or 2027 annual meeting
Vesting condition for entire option grant
Expiration date
June 23, 2036
Option term end date
Key Terms
Stock Option (right to buy), exercise price, vest in full, expiration date
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "10.5400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The shares subject to the option will vest in full on the earlier of June 24, 2027..."
expiration date financial
"expiration_date: "2036-06-23T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did ARS Pharmaceuticals (SPRY) director Phillip M. Schneider report in this Form 4?
Phillip M. Schneider reported receiving a grant of stock options for 30,000 shares of ARS Pharmaceuticals common stock. The options were awarded as compensation, not purchased on the open market, and give him the right to buy shares at a fixed exercise price.
What is the exercise price of Phillip M. Schneider’s ARS Pharmaceuticals (SPRY) stock options?
The options have an exercise price of $10.54 per share. This is the price at which Schneider can purchase ARS Pharmaceuticals common stock if he exercises the options during their term before expiration.
When do Phillip M. Schneider’s ARS Pharmaceuticals (SPRY) stock options vest?
The options vest in full on the earlier of June 24, 2027 or the date of ARS Pharmaceuticals’ 2027 annual stockholder meeting. The exact meeting date has not yet been set by the company’s board of directors.
What is the expiration date of Schneider’s ARS Pharmaceuticals (SPRY) stock options?
These stock options expire on June 23, 2036. If Schneider does not exercise the options by that date, his right to buy the 30,000 underlying ARS Pharmaceuticals common shares at $10.54 per share will lapse.